News

After successful completion of enrollment into the first STRAUSS trial (Study of Resistant Staphylococcus Aureus Skin and Skin Structure Infections), focusing on Gram-positive infections, the partnership now plans

The agreement provides Sanofi Pasteur with exclusive access to a portfolio of Agensys’ proprietary colorectal and prostate cancer targets, together with an option to obtain exclusive worldwide licenses

The main objective of this study is to assess the safety and tolerability of cintredekin besudotox administered via convection enhanced delivery (CED) followed by radiation therapy (RT) with

The optimized butyrylcholinesterase protein may have applications in biodefense as a bioscavenger protein for detoxifying nerve agents, and as a treatment for patients with cocaine or heroin drug

Three fractions of v38 AMF-1 were tested against H5N1, the virus responsible for causing avian influenza (bird flu), and all showed excellent potency and selectivity at inhibiting H5N1

Marketing of M-Vax started after recently receiving authorization from the Swiss Health authorities. The vaccine will be produced by Avax’s wholly owned subsidiary, Genopoietic, located in Lyon, France.

The data from preclinical studies in a rat collagen-induced arthritis model of chronic autoimmune inflammatory joint disease demonstrated that daily oral administration of 2-methoxyestradiol (2ME2) resulted in a

The drug is being developed for the treatment of chronic moderate-to-severe malignant (cancer-related) and non-malignant pain, such as osteoarthritis and lower-back. Alpharma has developed a proprietary technology that

Practitioners at the Clinic for Special Children in Pennsylvania are using GeneChip microarrays developed by Affymetrix to discover the genetic cause of diseases at an unprecedented pace. The